Mass spectrometry in structural and stereochemical problems. CCXXX. Preparation of 5.alpha.,20.alpha. and 5.alpha.,17.alpha.,20.alpha.-cholestane-3.beta.,6.alpha.-diol. Electron impact induced fragmentation of steroidal .DELTA.17(20), .DELTA.20(21) and .DELTA.20(22) olefins
[EN] INHIBITION OF PPAR GAMMA EXPRESSION IN PREADIPOCYTE CELLS BY OXYSTEROLS<br/>[FR] INHIBITION DE L'EXPRESSION DES PPAR GAMMA DANS LES CELLULES PRÉADIPOCYTAIRES AU MOYEN D'OXYSTÉROLS
申请人:UNIV CALIFORNIA
公开号:WO2011006087A1
公开(公告)日:2011-01-13
This invention relates, e.g., to methods and agents to inhibit peroxisome proliferator activated receptor expression (PPAR) in preadipocytes.
这项发明涉及抑制脂肪前体细胞中过氧化物酶体增殖激活受体表达(PPAR)的方法和药剂。
INHIBITION OF PPAR GAMMA EXPRESSION BY SPECIFIC OSTEOGENIC OXYSTEROLS
申请人:Parhami Farhad
公开号:US20100105645A1
公开(公告)日:2010-04-29
This invention relates to methods for using agents to inhibit peroxisome proliferator activated receptor expression.
本发明涉及使用药剂抑制过氧化物酶体增殖激活受体表达的方法。
Agents and Methods for Osteogenic Oxysterols Inhibition of Oxidative Stress on Osteogenic Cellular Differentiation
申请人:Parhami Farhad
公开号:US20090202660A1
公开(公告)日:2009-08-13
The present invention discloses oxygenic oxygenic oxysterols. Also disclosed, agents and methods for protecting, blocking or rescuing marrow stromal cells from the inhibitory effects of oxidative stress on their osteoblastic cellular differentiation. Exemplary agents include oxysterols, rhBMP2, alone or in combination which are demonstrated to specifically combat oxidative stress caused by inflammatory oxidized lipids, such as xanthine/xanthine oxidase and minimally oxidized LDL. The synergistic effects of oxysterols and bone morphogenic proteins are disclosed.
US8022052B2
申请人:——
公开号:US8022052B2
公开(公告)日:2011-09-20
[EN] INHIBITION OF PPAR GAMMA EXPRESSION BY SPECIFIC OSTEOGENIC OXYSTEROLS<br/>[FR] INHIBITION DE L'EXPRESSION DE PPAR GAMMA PAR DES OXYSTÉROLS OSTÉOGÈNES SPÉCIFIQUES
申请人:PARHAMI FARHAD
公开号:WO2008082520A2
公开(公告)日:2008-07-10
[EN] This invention relates to methods for using agents to inhibit peroxisome proliferator activated receptor expression. [FR] La présente invention concerne des procédés permettant l'utilisation d'agents pour inhiber l'expression du récepteur PPAR (Peroxisome Proliferator Activated Receptor).